Cadent Therapeutics wins milestone payment for initiation of NAM Phase 1 clinical studies in neurological conditions.
M2 EQUITYBITES-October 18, 2017-Cadent Therapeutics wins milestone payment for initiation of NAM Phase 1 clinical studies in neurological conditions
(C)2017 M2 COMMUNICATIONS http://www.m2.com
Precision neuroscience company Cadent Therapeutics reported on Tuesday that it expects a milestone payment from Novartis for the initiation of a Phase 1 clinical study of a subtype selective NMDA receptor negative allosteric modulator (NAM) for the treatment of treatment-resistant depression.
In conjunction with the payment, Cadent had exclusively licensed the intellectual property for compounds that selectively modulate NR2B-containing NMDA receptors to Novartis.
Under the terms of the agreement, Novartis is conducting all research and development for the programme. It has advanced the NR2B NAM molecule into clinical studies.
According to Cadent, it is discovering novel medicines designed to modulate dysregulated activity in the brain, tuning brain rhythms to restore motor and cognitive function. The company is advancing its pipeline of positive allosteric modulators for the treatment of spinocerebellar ataxia (SCA), essential tremor and cognitive impairment in patients with schizophrenia, with plans to enter the clinic in 2018.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Oct 18, 2017|
|Previous Article:||Corus Entertainment signs CAD200m sale agreement with Bell Media for Historia and SA(c)ries+.|
|Next Article:||FNFV closes acquisition of T-System Holdings for about USD200m cash.|